Mumbai: Biocon Ltd has announced the launch of BIOMAb-EGFR, a therapeutic monoclonal antibody-based drug for treating solid tumours of epithelial origin, such as head and neck cancers.
Announcing this, the company's release to BSE said this novel drug is designed to specifically target and arrest epidermal growth factor receptor (EGFR) responsible for the proliferation of cancer cells. BIOMAb-EGFR is the first drug of its kind to be clinically developed in India and is the first anti-EGFR humanised mono-clonal antibody for cancer to be made available commercially anywhere in the world.
It shall be available as a unit carton of four 10 ml vials and has been launched across the country. The launch marks the entry of Biocon into proprietary immunotherapeutics.
The company, through the launch, joins the exclusive league of monoclonal antibody developers globally. BIOMAb-EGFR is competitively priced, making cancer treatment more affordable.
BIOMAb-EGFR is indicated for use in combination with radiation therapy/ chemotherapy in patients with positive expression of EGFR in squamous cell carcinoma of head and neck cancer. In clinical trials, BIOMAb-EGFR showed extensive proliferation inhibition activity in non-small cell lung cancer, breast cancer, colorectal cancer, pancreatic cancer, and glioblastoma (brain tumors).
Comments
0 comment